ClinicalTrials.gg
RecruitingNCT05900895PHOEBEUpdated Nov 20, 2025

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

A Phase 1 interventional study of Olaparib and 17b-estradiol in Metastatic Breast Cancer, sponsored by Mary D Chamberlin. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Mary D Chamberlin · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.

Planned enrollment
47th of 51
6 · median 54
Started
2024
with 2 others
Phase 1
16 of 51
1 open now
Primary completion
2027-12
later than 19 of 24 live
Registered
48th of 51
by date

Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 47th largest by planned enrollment, is one of 3 that started in 2024, is one of 16 in phase 1, reaches primary completion later than 19 of the 24 other live ones, and was the 48th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing olaparib in Breast Neoplasms, or all of them as a file.
02

Study summary

Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

Read the detailed description

Patients with endocrine-resistant ER+/HER2- breast cancer are eligible. Patients will be treated with the combination of 17b-estradiol and olaparib for 2 cycles, and then treated with single-agent 17b-estradiol until disease progression. Clinical benefit, progression-free survival, objective response, tumor metabolic response, and toxicity will be determined.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • metastatic
  • locally advanced
  • estradiol therapy
  • olaparib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with ER+/- breast cancer.
  • or locoregional recurrence not amenable to treatment with curative intent.
  • Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • During study treatment, no concurrent anti-cancer therapies are allowed with the following exceptions:

    o Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) permitted.

  • Any cancer therapy or systemic chemotherapy in the last 3 weeks.
  • Any radiation therapy in the last 2 weeks.
  • Known CNS disease, unless clinically stable for ≥ 3 months.
  • Concomitant use of known strong or moderate inhibitors.
  • Persistent toxicities (≥ grade 2) caused by previous cancer therapy.
  • History of any of the following:

    • Deep venous thrombosis
    • Pulmonary embolism
    • Stroke
    • Acute myocardial infarction
    • Congestive heart failure
    • Previous not treated with curative intent, or with an estimated recurrence risk ≥30%
    • Severe renal impairment ( ≤ 30 mL/min).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Participants receive 2 cycles of olaparib in combination with 17b-estradiol and then continue to be treated with single-agent 17b-estradiol until disease progression.

    Drug: Olaparib · Drug: 17b-estradiol

Interventions

  • Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.

    Also known as: Lynparza

  • DrugEstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    17b-estradiol will be taken orally three times per day.

    Also known as: Estrace

06

What researchers measure

Primary outcomes

  1. Determine the Phase II dose of olaparib in combination with 17b-estradiol

    Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

    Time frame: 8 weeks

Secondary outcomes

  1. Clinical benefit rate

    The proportion of evaluable patients experiencing clinical benefit (stable disease at 24 weeks, complete or partial response per RECIST) will be measured.

    Time frame: 6 months

  2. Objective response rate

    The proportion of evaluable patients experiencing objective response (complete or partial response per RECIST) will be measured.

    Time frame: 6 months

  3. Progression-free survival

    Progression-free survival will be measured by measuring the length of time between the start of study treatment until the time of cancer progression or death from any cause.

    Time frame: 12 months

  4. Plasma Olaparib concentration

    The concentration of Olaparib in plasma will be measured over 6 hours.

    Time frame: 6 hours

  5. Plasma 17b-Estradiol/Estrone concentration

    The concentration of 17b-Estradiol/Estrone in plasma will be measured over 6 hours.

    Time frame: 6 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 41 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 13, 2023
StartActual
Jul 15, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05900895
Lead sponsor
Mary D Chamberlin
Responsible party
Mary D Chamberlin (Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center) — Sponsor-investigator
First posted
Jun 13, 2023
Start date
Jul 15, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 20, 2025

Study contacts

Research Nurse
Contact
Cancer.Research.Nurse@dartmouth.edu
1-800-639-6918
Mary Chamberlin, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion